Efficacy and Safety of Broncho-Vaxom in the First Episode of Pediatric Idiopathic Nephrotic Syndrome
Status:
Not yet recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
The main objective is to demonstrate, from the initial episode of nephrotic syndrome (NS) in
children with standard prednisolone treatment, once complete remission has occurred, that the
use of Broncho-Vaxom (administration for 6 months) may reduce the risk of subsequent relapse
during 12-month of follow-up.